Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
about
Erectile dysfunction and central obesity: an Italian perspectivePhosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaThe Wonders of Phosphodiesterase-5 Inhibitors: A Majestic HistoryA review of the efficacy and safety of mirodenafil in the management of erectile dysfunctionUdenafil for the treatment of erectile dysfunctionPenile revascularization--contemporary updateUdenafil: efficacy and tolerability in the management of erectile dysfunctionAvanafil for male erectile dysfunction: a systematic review and meta-analysis.Clinical correlates of enlarged prostate size in subjects with sexual dysfunctionAn open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsRisks and benefits of late onset hypogonadism treatment: an expert opinion.Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Daily dosing of PDE5 inhibitors: where does it fit in?Stem-cell therapy for erectile dysfunction.Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.The pharmacotherapy of male hypogonadism besides androgens.Avanafil - a further step to tailoring patient needs and expectations.PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.Avanafil for the treatment of erectile dysfunction.First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis.Green Tea Polyphenol EGCG Upregulates Tollip Expression by Suppressing Elf-1 Expression.The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis.EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil.An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study.Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction.Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma.
P2860
Q22241096-C8D9FE09-B0CC-4C0A-84D8-95DE72912F90Q24199135-F5F94378-E734-4B48-9B76-A49B4A00D46CQ26741387-B6B9731F-40FE-412C-B404-AECA15961C69Q26749094-D7A7D7B9-4DB7-4C63-B7CD-B0CA991E6829Q26851999-E3D3D287-9109-4454-8911-D527469113BAQ27015680-BB8432EC-BF3D-4CA5-8A57-3E214DF9ECEFQ28288359-4A1B8943-6E98-4466-8A5D-C6E9B013AB50Q33621456-66728B87-4D84-4187-9622-5A11122CD83CQ34433316-B1EAE2C7-A917-4D39-9341-417DDDDC2EB6Q34927979-A68231D7-B202-498A-B7CB-D8CC723129E8Q35328376-A6AB0CF4-1D1D-461B-9570-FE35AB605DFCQ36460566-585F8B6C-045E-4719-9307-86FB72A9FB3BQ37165019-097CF05E-DF9F-4271-939E-0AB2A7149AADQ37686844-A0F8FEFA-6382-4CFD-9CA2-5AE30818D1B0Q38107001-0DAD6212-A581-436A-8B4F-BDE8CE2ED245Q38115198-411762F9-6E14-4760-A07B-0AF9C2CBA5D2Q38148781-67F5352C-33BD-4859-9397-DE1A226B9F20Q38166600-A09B79D1-B231-48CD-8285-3113A3594958Q38241416-01D58449-291D-455E-88A4-56ED07AD9B32Q38293550-EB0CCD5C-B6EB-4D99-AFE4-3E856F930DB5Q38846047-04E5E516-3008-419B-9455-EDE83D922C30Q38891514-CC4BA7DC-6D55-4BED-A1D1-FA9B24530955Q38896836-4148DF24-D2A0-43D6-AD28-1A88416ABDD9Q38956366-420EBC88-1E26-41FC-83CB-FC7FF96BC260Q42693466-B8214594-9648-42BD-9FDF-24965C729DD3Q44980700-876CAC36-2946-454A-9666-00D691331557Q47734890-0A4AC89F-84D6-402E-9822-9D43E929C911Q47866490-367EC570-CC39-41C3-B731-84E6E63DB50FQ48529608-7F6BFBF6-42F8-4BAE-9EEB-80A7501D537AQ48955240-EE69D773-E5C6-4D12-AAFC-3703A40C3AACQ53097333-078B95A6-4929-483C-80ED-F9F6798F6DE8Q54235018-A3E8819D-CE69-48F6-8513-9CC747D882A9
P2860
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Phosphodiesterase type 5 (PDE5 ...... r drug for the proper patient.
@en
type
label
Phosphodiesterase type 5 (PDE5 ...... r drug for the proper patient.
@en
prefLabel
Phosphodiesterase type 5 (PDE5 ...... r drug for the proper patient.
@en
P2093
P1476
Phosphodiesterase type 5 (PDE5 ...... r drug for the proper patient.
@en
P2093
Andrea Rossi
Andrea Ungar
Elisa Razzoli
Nicola Mondaini
P304
P356
10.1111/J.1743-6109.2011.02473.X
P577
2011-10-13T00:00:00Z